1.	A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M06-873, 2007-002143-25, NCT00481091
2.	A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ABT4710n, 2009-012152-24, GP00763, NCT01087151
3.	A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M06-814, NCI-07-C-0006, NCI-P7060, ABBOTT-M06-814, NCT00408811, NCT00406809
4.	Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M11-069, NCT00982566
5.	A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M11-958, NCT01009073
6.	A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M10-957, NCT01021358
7.	A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M10-955, NCT01121133